Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Histone modifiers at the crossroads of oncolytic and oncogenic viruses

Molecular Therapy(2022)10.1016/j.ymthe.2022.02.006Source: DataRank Database

Histone modifiers at the crossroads of oncolytic and oncogenic viruses is a research paper published in Molecular Therapy (2022). On theSindex it has a DataRank of 0. It has been cited 12 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access12 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 1.52)OA: hybridTopics (38)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Norman Mapes ORCID,Devika Dua ORCID,Balveen Kaur ORCID,Sara A. Murphy ORCID

Live enrichment

PubMed:35143960 PMC:PMC9171252 OpenAlex:https://openalex.org/W4210904076

National Institutes of Health

Grant: P01CA163205

National Institutes of Health

Grant: R61NS112410

U.S. Department of Defense

Grant: BC200333

National Institutes of Health

Grant: 3P01CA163205-03S1

Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas

FWCI

1.52

Citation Percentile

0.8%

Citation Trend

2022

2023

2024

2025

2026

hybridLicense: cc-by-nc-nd

journalhttp://www.cell.com/article/S1525001622000892/pdf

publisherhttp://www.cell.com/article/S1525001622000892/pdf

publisherhttps://api.elsevier.com/content/article/PII:S1525001622000892?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1525001622000892?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.ymthe.2022.02.006

Fields of Study

Virus-based gene therapy researchRNA Interference and Gene DeliveryCAR-T cell therapy research0301 basic medicine0303 health sciences03 medical and health sciences

MeSH Terms

HistonesHumansNeoplasmsOncogenic VirusesOncolytic VirotherapyOncolytic Viruses

Keywords

Oncolytic virusEpigenomeEpigeneticsBiologyCancer researchCancerCancer cellCell cycleMalignant transformationGeneGeneticsGene expressionDNA methylationDNAGene therapyVirusesMethylationAcetylationHistoneEpigenetic ModifiersHistonesOncolytic VirotherapyOncolytic VirusesNeoplasmsHumansOncogenic Viruses

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Histone modifiers at the crossroads of oncolytic and oncogenic viruses

FAIR Checklist

Authors (4)

Funding (4 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)